Business Context and Reporting Period
This Form 8-K is filed by Dynamics Special Purpose Corp. (DYNS), a Delaware corporation and emerging growth company, on May 10, 2022, reporting events occurring on May 9, 2022. The filing concerns the proposed business combination between Dynamics and Senti Biosciences, Inc. (Senti), pursuant to a Business Combination Agreement dated December 19, 2021. Under the agreement, a merger subsidiary will merge with Senti, which will survive as a wholly-owned subsidiary of Dynamics.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The document focuses on corporate governance and capital structure adjustments related to the pending merger.
Material Changes
On May 9, 2022, the Company entered into amendments (the "NRA Amendments") to existing Non-Redemption Agreements with key investors, including funds managed by Morgan Stanley, T. Rowe Price, The Invus Group, and ARK Investment Management. The material changes include:
- Adjustment of Sponsor Forfeiture: The Sponsor (Dynamics Sponsor LLC) agreed to forfeit a number of Class B Common Stock shares equal to 11.111% of the Investor Shares held by each applicable Investor at the time the Merger is consummated. This replaces the prior calculation based on shares held when the original Non-Redemption Agreement was signed.
- Share Issuance: Upon consummation of the Merger, the Company will cancel the forfeited Sponsor Shares and issue an equivalent number of Class A Common Stock shares to the Investors.
- Original Commitment: Prior to this amendment, the Sponsor had agreed to forfeit 965,728 shares (approximately 11.111% of the original Investor Shares).
Guidance, Outlook, and Risks
Outlook and Status: The definitive proxy statement/prospectus for the merger was filed with the SEC on February 14, 2022, and amended multiple times through May 10, 2022. The Registration Statement is not yet effective. The filing contains forward-looking statements regarding the timing, structure, and benefits of the Merger, as well as Senti's product development activities.
Risks and Contingencies: The completion of the Merger is subject to significant risks, including:
- Failure to obtain stockholder approval or satisfy other closing conditions.
- Termination of the Business Combination Agreement.
- Impact of the COVID-19 pandemic on Senti's business.
- Ability to maintain Nasdaq listing post-merger.
- Legal proceedings and regulatory changes.
The Company explicitly states it has no current intention to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the status of the Registration Statement (Form S-4) and the definitive proxy statement/prospectus for the proposed merger.
- Confirm the exact number of Investor Shares held by Morgan Stanley, T. Rowe Price, Invus, and ARK at the time of Merger consummation to calculate the final Sponsor forfeiture.
- Review the "Risk Factors" section in the Registration Statement for detailed disclosures on clinical trial outcomes and regulatory hurdles for Senti.
- Monitor for the effectiveness of the proxy statement and the scheduled shareholder meeting date.